{"success":true,"data":{"pressRelease":{"id":"53637","rtpr_id":"nPn97LBX7a","ticker":"RNAZ","exchange":"NASDAQ","all_tickers":["RNAZ"],"title":"TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer","author":"PR Newswire","published_at":"2026-06-03T12:04:00.262Z","article_body":"TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer\n\nPR Newswire\n\nBOSTON, June 3, 2026\n\nTransCode reports no dose-limiting toxicities, durable disease stabilization\nin metastatic patients; advances to Phase 2 development in ctDNA-positive\ncancers using next-generation RNA therapeutics.\n\nBOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:\nRNAZ) a clinical stage company pioneering immuno-oncology and RNA for the\ntreatment of high risk and advanced cancer, today announced further results of\nthe Phase 1a dose escalation clinical trial. The trial met its primary\nendpoint of safety, with positive tolerability, combined with disease\nstabilization in multiple patients, and the absence of dose-limiting\ntoxicities with its lead therapeutic candidate TTX-MC138. TTX-MC138, an\ninvestigational inhibitor of the key metastatic driver, microRNA-10b, has\nshown durable disease control. These findings support advancing TTX-MC138 into\nPhase 2a clinical development to assess efficacy in patients with circulating\ntumor DNA (ctDNA) positive colorectal cancer following curative–intent\ntherapy.\n\nTTX-MC138 has been administered to 16 patients who received 86 doses. The\nmedian treatment duration was 11.3 weeks, with a range of four to 52.4 weeks,\nrepresenting 2 to 20 cycles of treatment.\nNotably, three patients remain on trial, and continue to receive TTX-MC138.\nOne patient is at 21 cycles of treatment, another is at 16 cycles, and the\nthird one is at 14 cycles of treatment. (Table 1)\n Table 1: Trial demographics, met safety primary endpoint\n\n Cohort  Dose         Number of Patients  DLT's(1)\n 1       0.8mg/kg     3                   0\n 2(3)    1.6mg/kg     3                   0\n 3(3)    3.2mg/kg(2)  7                   0\n 4(3)    4.8mg/kg     3                   0\n (1 )No significant treatment-related safety events or dose limiting\n toxicities were observed.\n (2 )Optional backfill 3 with additional patients.\n (3 )One patient in each of cohort 2, 3 and 4 currently on study.\n\nTransCode believes these results support its selection of the recommended\nPhase 2a dose (RP2D) of 4.8mg/kg.\n\nIn addition, the assessment of the trial patient population underscored the\npotential for durable disease control in participants with metastatic cancer.\n\nBased on Response Evaluation Criteria in Solid Tumors (RECIST) standardized\ncriteria to measure tumor response to treatment using imaging to categorize\nlesions and assess changes in size over time, 9 out of 14 (64%) of evaluable\npatients achieved stable disease lasting six months, demonstrating a durable\ndisease activity.\n\n\"From a clinical perspective, it is quite encouraging to see how well\ntolerated this agent has been at the exposures achieved through the Phase 1a\ndose-escalation study, without any dose-limiting toxicities. That, combined\nwith the observation of disease stabilization in a population with such\nadvanced disease supports continued clinical development\" noted Keith\nFlaherty, MD, Director of Clinical Research at the Massachusetts General\nHospital Cancer Center, Professor of Medicine at Harvard Medical School and\nTransCode's Advisory Board member.\n\nThe pharmacokinetics profile from the analysis of plasma from patients\nreceiving TTX-MC138 demonstrated evidence of drug bioavailability consistent\nwith earlier preclinical studies.\n\nOne patient diagnosed with metastatic thyroid cancer was noted to have a\ndramatic decrease in their thyroglobulin levels, a tumor marker associated\nwith cancer progression. The patient has now had demonstrated stable disease\nfor the last 12 months and is one of the three patients who remain on study.\nWe believe that the patient's continued participation in the study, together\nwith the decline in their thyroglobulin levels, provides further evidence of\ntherapeutic activity from TTX-MC138.\n\nA clinical study report is in process. Several presentations are planned at\nfuture scientific congresses.\n\n\"As the safety and tolerability primary objectives of the trial were met, the\nencouraging rates of disease stabilization provide the rationale to advance\nTTX-MC138 clinical development in our recently initiated Phase 2a trial. We\ncontinue to believe that TTX-MC138 may offer a promising therapeutic option,\nif approved, for patients with metastatic disease who have limited treatment\nalternatives,\" said Daniel Vlock, MD, TransCode Consulting Clinician.\n\nFurther information about the trial is available at www.clinicaltrials.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702528-1&h=2065006101&u=http%3A%2F%2Fwww.clinicaltrials.gov%2F&a=www.clinicaltrials.gov)\n, (NCT Identifier: NCT06260774).\n\nAbout TTX-MC138\n\nTTX-MC138 is a first-in-class therapeutic candidate designed to inhibit\nmicroRNA-10b (miR-10b), a microRNA widely believed to be critical to the\nemergence and progression of many metastatic cancers. TransCode's Phase 0\nclinical trial produced evidence of delivery of a radiolabeled version of\nTTX-MC138 to metastatic lesions.\n\nAbout TransCode Therapeutics\n\nTransCode Therapeutics is an immuno-oncology and targeted cancer therapy\ncompany with a focus on treating advanced malignancy.  The Company's lead\ntherapeutic candidate, TTX-MC138, is focused on treating metastatic tumors\nthat overexpress microRNA-10b, a unique, well-documented biomarker of\nmetastasis. In addition, TransCode has a portfolio of other first-in-class\ntherapeutic candidates designed to mobilize the immune system to recognize and\ndestroy cancer cells.\n\nForward-Looking Statements\n\nThis release contains \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995, including, without\nlimitation, statements concerning the timing, conduct and results of\nTransCode's Phase 1a and Phase 2a clinical trials, statements about microRNAs\nand their involvement in cancer, and statements concerning the therapeutic\npotential of TransCode's TTX-MC138 and other therapeutic candidates. Any\nforward-looking statements in this press release are based on management's\ncurrent expectations of future events and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. These risks and uncertainties include, but are not limited to: the\nrisks associated with drug discovery and development; the risk that the\nresults of clinical trials will not be consistent with TransCode's preclinical\nstudies or expectations or with results from previous clinical trials; risks\nassociated with the conduct of clinical trials; risks associated with\nTransCode's financial condition and its need to obtain additional funding to\nsupport its business activities, including TransCode's ability to continue as\na going concern; risks associated with the timing and outcome of TransCode's\nplanned regulatory submissions; risks associated with obtaining, maintaining\nand protecting intellectual property; risks associated with TransCode's\nability to enforce its patents against infringers and defend its patent\nportfolio against challenges from third parties; risks of competition from\nother companies developing products for similar uses; risks associated with\nTransCode's dependence on third parties; and risks associated with\ngeopolitical events and pandemics. For a discussion of these and other risks\nand uncertainties, and other important factors, any of which could cause\nTransCode's actual results to differ from those contained in or implied by the\nforward-looking statements, see the section entitled \"Risk Factors\" in\nTransCode's Annual Report on Form 10-K for the year ended December 31, 2025,\nas well as discussions of potential risks, uncertainties and other important\nfactors in any subsequent TransCode filings with the U.S. Securities and\nExchange Commission. All information in this press release is as of the date\nof this release; TransCode undertakes no duty to update this information\nunless required by law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-successfully-completes-phase-1a-clinical-trial-reports-safety-and-stabilization-data-for-ttx-mc138-in-metastatic-cancer-302789380.html\n(https://www.prnewswire.com/news-releases/transcode-therapeutics-successfully-completes-phase-1a-clinical-trial-reports-safety-and-stabilization-data-for-ttx-mc138-in-metastatic-cancer-302789380.html)\n\nSOURCE TransCode Therapeutics, Inc.\n\n\n\nFor more information and partnering opportunities, please contact: TransCode Therapeutics, Inc., Tania Montgomery, VP of Business Development, tania.montgomery@transcodetherapeutics.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1853420/Picture1-ID-6d0e28bfd5a5.jpg?id=OA2644566\nhttps://mmx.prnewswire.com/media/MS1773301/TransCode_Therapeutics_Inc.jpg?id=OA2644461\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn97LBX7a","title":"TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer","author":"PR Newswire","ticker":"RNAZ","created":"2026-06-03T12:04:00.262Z","tickers":["RNAZ"],"exchange":"NASDAQ","article_body":"TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer\n\nPR Newswire\n\nBOSTON, June 3, 2026\n\nTransCode reports no dose-limiting toxicities, durable disease stabilization\nin metastatic patients; advances to Phase 2 development in ctDNA-positive\ncancers using next-generation RNA therapeutics.\n\nBOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:\nRNAZ) a clinical stage company pioneering immuno-oncology and RNA for the\ntreatment of high risk and advanced cancer, today announced further results of\nthe Phase 1a dose escalation clinical trial. The trial met its primary\nendpoint of safety, with positive tolerability, combined with disease\nstabilization in multiple patients, and the absence of dose-limiting\ntoxicities with its lead therapeutic candidate TTX-MC138. TTX-MC138, an\ninvestigational inhibitor of the key metastatic driver, microRNA-10b, has\nshown durable disease control. These findings support advancing TTX-MC138 into\nPhase 2a clinical development to assess efficacy in patients with circulating\ntumor DNA (ctDNA) positive colorectal cancer following curative–intent\ntherapy.\n\nTTX-MC138 has been administered to 16 patients who received 86 doses. The\nmedian treatment duration was 11.3 weeks, with a range of four to 52.4 weeks,\nrepresenting 2 to 20 cycles of treatment.\nNotably, three patients remain on trial, and continue to receive TTX-MC138.\nOne patient is at 21 cycles of treatment, another is at 16 cycles, and the\nthird one is at 14 cycles of treatment. (Table 1)\n Table 1: Trial demographics, met safety primary endpoint\n\n Cohort  Dose         Number of Patients  DLT's(1)\n 1       0.8mg/kg     3                   0\n 2(3)    1.6mg/kg     3                   0\n 3(3)    3.2mg/kg(2)  7                   0\n 4(3)    4.8mg/kg     3                   0\n (1 )No significant treatment-related safety events or dose limiting\n toxicities were observed.\n (2 )Optional backfill 3 with additional patients.\n (3 )One patient in each of cohort 2, 3 and 4 currently on study.\n\nTransCode believes these results support its selection of the recommended\nPhase 2a dose (RP2D) of 4.8mg/kg.\n\nIn addition, the assessment of the trial patient population underscored the\npotential for durable disease control in participants with metastatic cancer.\n\nBased on Response Evaluation Criteria in Solid Tumors (RECIST) standardized\ncriteria to measure tumor response to treatment using imaging to categorize\nlesions and assess changes in size over time, 9 out of 14 (64%) of evaluable\npatients achieved stable disease lasting six months, demonstrating a durable\ndisease activity.\n\n\"From a clinical perspective, it is quite encouraging to see how well\ntolerated this agent has been at the exposures achieved through the Phase 1a\ndose-escalation study, without any dose-limiting toxicities. That, combined\nwith the observation of disease stabilization in a population with such\nadvanced disease supports continued clinical development\" noted Keith\nFlaherty, MD, Director of Clinical Research at the Massachusetts General\nHospital Cancer Center, Professor of Medicine at Harvard Medical School and\nTransCode's Advisory Board member.\n\nThe pharmacokinetics profile from the analysis of plasma from patients\nreceiving TTX-MC138 demonstrated evidence of drug bioavailability consistent\nwith earlier preclinical studies.\n\nOne patient diagnosed with metastatic thyroid cancer was noted to have a\ndramatic decrease in their thyroglobulin levels, a tumor marker associated\nwith cancer progression. The patient has now had demonstrated stable disease\nfor the last 12 months and is one of the three patients who remain on study.\nWe believe that the patient's continued participation in the study, together\nwith the decline in their thyroglobulin levels, provides further evidence of\ntherapeutic activity from TTX-MC138.\n\nA clinical study report is in process. Several presentations are planned at\nfuture scientific congresses.\n\n\"As the safety and tolerability primary objectives of the trial were met, the\nencouraging rates of disease stabilization provide the rationale to advance\nTTX-MC138 clinical development in our recently initiated Phase 2a trial. We\ncontinue to believe that TTX-MC138 may offer a promising therapeutic option,\nif approved, for patients with metastatic disease who have limited treatment\nalternatives,\" said Daniel Vlock, MD, TransCode Consulting Clinician.\n\nFurther information about the trial is available at www.clinicaltrials.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702528-1&h=2065006101&u=http%3A%2F%2Fwww.clinicaltrials.gov%2F&a=www.clinicaltrials.gov)\n, (NCT Identifier: NCT06260774).\n\nAbout TTX-MC138\n\nTTX-MC138 is a first-in-class therapeutic candidate designed to inhibit\nmicroRNA-10b (miR-10b), a microRNA widely believed to be critical to the\nemergence and progression of many metastatic cancers. TransCode's Phase 0\nclinical trial produced evidence of delivery of a radiolabeled version of\nTTX-MC138 to metastatic lesions.\n\nAbout TransCode Therapeutics\n\nTransCode Therapeutics is an immuno-oncology and targeted cancer therapy\ncompany with a focus on treating advanced malignancy.  The Company's lead\ntherapeutic candidate, TTX-MC138, is focused on treating metastatic tumors\nthat overexpress microRNA-10b, a unique, well-documented biomarker of\nmetastasis. In addition, TransCode has a portfolio of other first-in-class\ntherapeutic candidates designed to mobilize the immune system to recognize and\ndestroy cancer cells.\n\nForward-Looking Statements\n\nThis release contains \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995, including, without\nlimitation, statements concerning the timing, conduct and results of\nTransCode's Phase 1a and Phase 2a clinical trials, statements about microRNAs\nand their involvement in cancer, and statements concerning the therapeutic\npotential of TransCode's TTX-MC138 and other therapeutic candidates. Any\nforward-looking statements in this press release are based on management's\ncurrent expectations of future events and are subject to a number of risks and\nuncertainties that could cause actual results to differ materially and\nadversely from those set forth in or implied by such forward-looking\nstatements. These risks and uncertainties include, but are not limited to: the\nrisks associated with drug discovery and development; the risk that the\nresults of clinical trials will not be consistent with TransCode's preclinical\nstudies or expectations or with results from previous clinical trials; risks\nassociated with the conduct of clinical trials; risks associated with\nTransCode's financial condition and its need to obtain additional funding to\nsupport its business activities, including TransCode's ability to continue as\na going concern; risks associated with the timing and outcome of TransCode's\nplanned regulatory submissions; risks associated with obtaining, maintaining\nand protecting intellectual property; risks associated with TransCode's\nability to enforce its patents against infringers and defend its patent\nportfolio against challenges from third parties; risks of competition from\nother companies developing products for similar uses; risks associated with\nTransCode's dependence on third parties; and risks associated with\ngeopolitical events and pandemics. For a discussion of these and other risks\nand uncertainties, and other important factors, any of which could cause\nTransCode's actual results to differ from those contained in or implied by the\nforward-looking statements, see the section entitled \"Risk Factors\" in\nTransCode's Annual Report on Form 10-K for the year ended December 31, 2025,\nas well as discussions of potential risks, uncertainties and other important\nfactors in any subsequent TransCode filings with the U.S. Securities and\nExchange Commission. All information in this press release is as of the date\nof this release; TransCode undertakes no duty to update this information\nunless required by law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-successfully-completes-phase-1a-clinical-trial-reports-safety-and-stabilization-data-for-ttx-mc138-in-metastatic-cancer-302789380.html\n(https://www.prnewswire.com/news-releases/transcode-therapeutics-successfully-completes-phase-1a-clinical-trial-reports-safety-and-stabilization-data-for-ttx-mc138-in-metastatic-cancer-302789380.html)\n\nSOURCE TransCode Therapeutics, Inc.\n\n\n\nFor more information and partnering opportunities, please contact: TransCode Therapeutics, Inc., Tania Montgomery, VP of Business Development, tania.montgomery@transcodetherapeutics.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1853420/Picture1-ID-6d0e28bfd5a5.jpg?id=OA2644566\nhttps://mmx.prnewswire.com/media/MS1773301/TransCode_Therapeutics_Inc.jpg?id=OA2644461\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-03T12:04:00.324682974Z","server_sent_at_ms":1780488240324},"received_at":"2026-06-03T12:04:00.393Z","source_url":"https://www.prnewswire.com/news-releases/transcode-therapeutics-successfully-completes-phase-1a-clinical-trial-reports-safety-and-stabilization-data-for-ttx-mc138-in-metastatic-cancer-302789380.html"},"analysis":{"id":"43067","press_release_id":"53637","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Company cites risks associated with financial condition and need for additional funding in forward-looking statements","Small patient cohort (16 patients) limits statistical power of stabilization data"],"eventType":"clinical_trial","narrative":"TransCode Therapeutics completed its Phase 1a dose-escalation trial for TTX-MC138, meeting the primary safety endpoint with no dose-limiting toxicities observed across 16 patients.\n\nThe data showed durable disease stabilization in 64% of evaluable patients, with three individuals remaining on treatment for up to 21 cycles, supporting the selection of a 4.8mg/kg recommended Phase 2 dose.\n\nThe company will advance TTX-MC138 into Phase 2a development to assess efficacy in ctDNA-positive colorectal cancer patients following curative-intent therapy.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Clean Phase 1a readout for RNAZ's lead asset with no DLTs and durable stabilization; advancing to Phase 2a in colorectal cancer."},"keyFigures":{"drugName":"TTX-MC138","phaseOfTrial":"Phase 1a","customDimensions":{"patients_treated":16,"doses_administered":86,"evaluable_patients":14,"stable_disease_rate":"64%","stable_disease_patients":9,"recommended_phase_2_dose":"4.8mg/kg","patients_remaining_on_study":3,"median_treatment_duration_weeks":11.3}},"quotedText":"From a clinical perspective, it is quite encouraging to see how well tolerated this agent has been at the exposures achieved through the Phase 1a dose-escalation study, without any dose-limiting toxicities.","namedEntities":{"people":[{"name":"Keith Flaherty","role":"Director of Clinical Research, Massachusetts General Hospital Cancer Center; Advisory Board member"},{"name":"Daniel Vlock","role":"TransCode Consulting Clinician"},{"name":"Tania Montgomery","role":"VP of Business Development"}],"products":["TTX-MC138","microRNA-10b"],"companies":[{"name":"TransCode Therapeutics, Inc.","ticker":"RNAZ"},{"name":"Massachusetts General Hospital Cancer Center","relationship":"clinical research partner"},{"name":"Harvard Medical School","relationship":"academic affiliation"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Successful completion of Phase 1a with no dose-limiting toxicities and durable disease stabilization in 64% of evaluable patients. This de-risks the lead asset and supports advancement to Phase 2a, a critical milestone for a clinical-stage biotech."},"tickerRelevance":{"others":[],"primary":"RNAZ"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"phase_1_completion","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"TransCode Therapeutics completed its Phase 1a dose-escalation trial for TTX-MC138, meeting the primary safety endpoint with no dose-limiting toxicities observed across 16 patients.\n\nThe data showed durable disease stabilization in 64% of evaluable patients, with three individuals remaining on treatment for up to 21 cycles, supporting the selection of a 4.8mg/kg recommended Phase 2 dose.\n\nThe company will advance TTX-MC138 into Phase 2a development to assess efficacy in ctDNA-positive colorectal cancer patients following curative-intent therapy.","key_figures":{"drugName":"TTX-MC138","phaseOfTrial":"Phase 1a","customDimensions":{"patients_treated":16,"doses_administered":86,"evaluable_patients":14,"stable_disease_rate":"64%","stable_disease_patients":9,"recommended_phase_2_dose":"4.8mg/kg","patients_remaining_on_study":3,"median_treatment_duration_weeks":11.3}},"named_entities":{"people":[{"name":"Keith Flaherty","role":"Director of Clinical Research, Massachusetts General Hospital Cancer Center; Advisory Board member"},{"name":"Daniel Vlock","role":"TransCode Consulting Clinician"},{"name":"Tania Montgomery","role":"VP of Business Development"}],"products":["TTX-MC138","microRNA-10b"],"companies":[{"name":"TransCode Therapeutics, Inc.","ticker":"RNAZ"},{"name":"Massachusetts General Hospital Cancer Center","relationship":"clinical research partner"},{"name":"Harvard Medical School","relationship":"academic affiliation"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T06:00:29.921Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"phase_1_completion","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":40935,"modelName":"george-droid-qwen-72b"}}